Posted by Michael Wonder on 19 Dec 2024
Lilly's Kisunla (donanemab-azbt) approved in China for the treatment of early symptomatic Alzheimer's disease
17 December 2024 - China is the fourth major market where Kisunla has received approval.
Eli Lilly today announced that the National Medical Products Administration in China has approved Kisunla (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly's Alzheimer's treatment for adults with early symptomatic Alzheimer's disease, which includes people with mild cognitive impairment as well as people with the mild dementia stage of Alzheimer's disease who have confirmed amyloid pathology.
